NEW YORK, April 29, 2014 /PRNewswire/ -- IntelliCell BioSciences, Inc. ("IntelliCell" or the "Company") (OTCQB:SVFC), a regenerative medicine company utilizing adult autologous Stromal Vascular Cells (SVCs) derived from the blood vessels found in adipose tissue, announced today that it supplied its Stromal Vascular Fraction Cells, manufactured using its patented ultrasonic technology, for the restoration of cardiac function at the University of Arizona College of Medicine, Tucson in collaboration with Dr. Zain Khalpey, Division of Cardiothoracic Surgery. The autologous cells were gathered on site with Institutional Review Board approval in accordance with all applicable regulatory requirements. The case was reported in Clinical Communication to the Editor in The American Journal of Medicine Vol.127, No 5, May 2014.
According to Dr. Zain Khalpey's conclusions in the clinical communications to The American Journal of Medicine, "We postulate that the intramyocardial administration of multi-potent adipose-derived stromal vascular fraction cells and their diverse composition guided engraftment in the damaged area, facilitated the cardiomyocyte regenerative properties, and helped improve cardiac function. Because subcutaneous adipose tissue is readily available in most patients, adipose-derived stromal vascular fraction cells present a feasible clinical intervention for cardiac dysfunction. The population complexity, which includes stromal vascular fraction and growth factors, likely promotes repair by recruiting cardiomyocytes. The autologous nature and multi-potency of these cells may contribute to them being ideal for cardiac function restoration."
IntelliCell's Chief Executive Officer, Dr. Steven Victor, remarked, "This is a momentous point for Intellicell Biosciences illustrating that its Stromal Vascular Fraction Cells (SVFC) and its technology have clinical promise in the restoration of cardiac function. I believe Dr. Khalpey's theory of injecting the SVFCs intracardiac externally and intravenously under a compassionate IRB, will pave the way for our FDA IND study that will focus on Congestive Heart Failure. This IND study will be important for proving the company's patented technology of Ultrasonic Cavitation as a method of separating stromal vascular fraction cells from lipoaspirate. We believe that IntelliCell's Stromal Vascular Fraction Cells injected into the cardiac muscle externally and given intravenously will make a significant clinical difference.